HRP20100389T1 - Spojevi benzimidazola - Google Patents
Spojevi benzimidazola Download PDFInfo
- Publication number
- HRP20100389T1 HRP20100389T1 HR20100389T HRP20100389T HRP20100389T1 HR P20100389 T1 HRP20100389 T1 HR P20100389T1 HR 20100389 T HR20100389 T HR 20100389T HR P20100389 T HRP20100389 T HR P20100389T HR P20100389 T1 HRP20100389 T1 HR P20100389T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- salt
- solvate
- compound
- methyl
- Prior art date
Links
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract 38
- 239000012453 solvate Substances 0.000 claims abstract 38
- 150000001875 compounds Chemical class 0.000 claims abstract 35
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 22
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 11
- -1 methylenedioxy group Chemical group 0.000 claims abstract 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 8
- 125000005843 halogen group Chemical group 0.000 claims abstract 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract 6
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 3
- 125000002947 alkylene group Chemical group 0.000 claims abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 14
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 10
- 229910052731 fluorine Inorganic materials 0.000 claims 9
- 125000001153 fluoro group Chemical group F* 0.000 claims 9
- 239000002253 acid Substances 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 201000006549 dyspepsia Diseases 0.000 claims 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 5
- 230000000069 prophylactic effect Effects 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- 208000025865 Ulcer Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 208000000718 duodenal ulcer Diseases 0.000 claims 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 231100000397 ulcer Toxicity 0.000 claims 4
- 208000007107 Stomach Ulcer Diseases 0.000 claims 3
- 201000005917 gastric ulcer Diseases 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 206010002243 Anastomotic ulcer Diseases 0.000 claims 2
- 208000007882 Gastritis Diseases 0.000 claims 2
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 239000003899 bactericide agent Substances 0.000 claims 2
- 230000003628 erosive effect Effects 0.000 claims 2
- 210000001156 gastric mucosa Anatomy 0.000 claims 2
- 201000000052 gastrinoma Diseases 0.000 claims 2
- 208000024798 heartburn Diseases 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- IOTXLNFGBVIKPF-UHFFFAOYSA-N 2-[[3-methyl-4-(1,5,9-trioxaspiro[5.5]undecan-3-ylmethoxy)pyridin-2-yl]methylsulfinyl]-1h-benzimidazole Chemical compound CC1=C(CS(=O)C=2NC3=CC=CC=C3N=2)N=CC=C1OCC(CO1)COC21CCOCC2 IOTXLNFGBVIKPF-UHFFFAOYSA-N 0.000 claims 1
- PTGBKPZTLZSJIG-UHFFFAOYSA-N 2-[[3-methyl-4-[(8-methyl-1,4,7,9-tetraoxaspiro[4.5]decan-8-yl)methoxy]pyridin-2-yl]methylsulfinyl]-1h-benzimidazole Chemical compound CC1=C(CS(=O)C=2NC3=CC=CC=C3N=2)N=CC=C1OCC(OC1)(C)OCC21OCCO2 PTGBKPZTLZSJIG-UHFFFAOYSA-N 0.000 claims 1
- AZGVKNPVQMGIHS-UHFFFAOYSA-N 2-[[4-(1,3-dioxolan-4-ylmethoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1h-benzimidazole Chemical compound CC1=C(CS(=O)C=2NC3=CC=CC=C3N=2)N=CC=C1OCC1COCO1 AZGVKNPVQMGIHS-UHFFFAOYSA-N 0.000 claims 1
- MKGXSTCRHKKBDO-UHFFFAOYSA-N 2-[[4-(5,7-dioxaspiro[2.5]octan-6-ylmethoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1h-benzimidazole Chemical compound CC1=C(CS(=O)C=2NC3=CC=CC=C3N=2)N=CC=C1OCC(OC1)OCC21CC2 MKGXSTCRHKKBDO-UHFFFAOYSA-N 0.000 claims 1
- ZWTOWWUEUVANKO-UHFFFAOYSA-N 2-[[4-(5,9-dioxaspiro[3.5]nonan-7-ylmethoxy)pyridin-2-yl]methylsulfinyl]-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1S(=O)CC(N=CC=1)=CC=1OCC(CO1)COC21CCC2 ZWTOWWUEUVANKO-UHFFFAOYSA-N 0.000 claims 1
- FBBJHLVGYGVBLE-UHFFFAOYSA-N 2-[[4-(5,9-dioxaspiro[3.5]nonan-7-yloxy)-3-methylpyridin-2-yl]methylsulfinyl]-1h-benzimidazole Chemical compound CC1=C(CS(=O)C=2NC3=CC=CC=C3N=2)N=CC=C1OC(CO1)COC21CCC2 FBBJHLVGYGVBLE-UHFFFAOYSA-N 0.000 claims 1
- JSQBHPGRXGUKOR-UHFFFAOYSA-N 2-[[4-(5,9-dioxaspiro[3.5]nonan-7-yloxy)pyridin-2-yl]methylsulfinyl]-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1S(=O)CC(N=CC=1)=CC=1OC(CO1)COC21CCC2 JSQBHPGRXGUKOR-UHFFFAOYSA-N 0.000 claims 1
- DWDKHTXMLSZGDL-UHFFFAOYSA-N 2-[[4-[(2,2-dimethyl-1,3-dioxan-5-yl)methoxy]-3,5-dimethylpyridin-2-yl]methylsulfinyl]-1h-benzimidazole Chemical compound CC1=CN=C(CS(=O)C=2NC3=CC=CC=C3N=2)C(C)=C1OCC1COC(C)(C)OC1 DWDKHTXMLSZGDL-UHFFFAOYSA-N 0.000 claims 1
- ZQOBAQHSXAQQLI-UHFFFAOYSA-N 2-[[4-[(2-methoxy-1,3-dioxan-5-yl)methoxy]-3-methylpyridin-2-yl]methylsulfinyl]-1h-benzimidazole Chemical compound C1OC(OC)OCC1COC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C ZQOBAQHSXAQQLI-UHFFFAOYSA-N 0.000 claims 1
- CWTLNABPUFBAGT-UHFFFAOYSA-N 2-[[4-[(5,5-difluoro-1,3-dioxan-2-yl)methoxy]-3-methylpyridin-2-yl]methylsulfinyl]-1h-benzimidazole Chemical compound C1=CN=C(CS(=O)C=2NC3=CC=CC=C3N=2)C(C)=C1OCC1OCC(F)(F)CO1 CWTLNABPUFBAGT-UHFFFAOYSA-N 0.000 claims 1
- XPSQFXMHDZHDFH-UHFFFAOYSA-N 2-[[4-[(5,5-dimethyl-1,3-dioxan-2-yl)methoxy]-3-methylpyridin-2-yl]methylsulfinyl]-1h-benzimidazole Chemical compound CC1=C(CS(=O)C=2NC3=CC=CC=C3N=2)N=CC=C1OCC1OCC(C)(C)CO1 XPSQFXMHDZHDFH-UHFFFAOYSA-N 0.000 claims 1
- NSZDOQZLRNHVPY-UHFFFAOYSA-N 2-[[4-[[2,2-bis(fluoromethyl)-1,3-dioxan-5-yl]methoxy]-3-methylpyridin-2-yl]methylsulfinyl]-1h-benzimidazole Chemical compound C1=CN=C(CS(=O)C=2NC3=CC=CC=C3N=2)C(C)=C1OCC1COC(CF)(CF)OC1 NSZDOQZLRNHVPY-UHFFFAOYSA-N 0.000 claims 1
- 206010000060 Abdominal distension Diseases 0.000 claims 1
- 206010000087 Abdominal pain upper Diseases 0.000 claims 1
- 208000023514 Barrett esophagus Diseases 0.000 claims 1
- 208000023665 Barrett oesophagus Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 206010017865 Gastritis erosive Diseases 0.000 claims 1
- 206010017866 Gastritis haemorrhagic Diseases 0.000 claims 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 claims 1
- 241000590002 Helicobacter pylori Species 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 206010021518 Impaired gastric emptying Diseases 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- 206010067171 Regurgitation Diseases 0.000 claims 1
- 206010042220 Stress ulcer Diseases 0.000 claims 1
- 206010061577 Ulcer haemorrhage Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 208000024330 bloating Diseases 0.000 claims 1
- 206010006514 bruxism Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 230000027119 gastric acid secretion Effects 0.000 claims 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 claims 1
- 208000001288 gastroparesis Diseases 0.000 claims 1
- 229940037467 helicobacter pylori Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000011906 peptic ulcer disease Diseases 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000035807 sensation Effects 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 210000001738 temporomandibular joint Anatomy 0.000 claims 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005117643 | 2005-04-15 | ||
| US67584805P | 2005-04-29 | 2005-04-29 | |
| PCT/JP2006/308069 WO2006112442A1 (ja) | 2005-04-15 | 2006-04-17 | ベンズイミダゾール化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100389T1 true HRP20100389T1 (hr) | 2010-08-31 |
Family
ID=37115157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100389T HRP20100389T1 (hr) | 2005-04-15 | 2010-07-15 | Spojevi benzimidazola |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20070015782A1 (el) |
| EP (1) | EP1870409B1 (el) |
| JP (1) | JP4949246B2 (el) |
| KR (1) | KR101285696B1 (el) |
| AU (1) | AU2006237974B2 (el) |
| BR (1) | BRPI0608400B8 (el) |
| CA (1) | CA2602610C (el) |
| CY (1) | CY1110074T1 (el) |
| DE (1) | DE602006014261D1 (el) |
| DK (1) | DK1870409T3 (el) |
| ES (1) | ES2344467T3 (el) |
| HK (1) | HK1117826A1 (el) |
| HR (1) | HRP20100389T1 (el) |
| IL (1) | IL186282A (el) |
| ME (1) | ME01855B (el) |
| NO (1) | NO339502B1 (el) |
| NZ (1) | NZ561920A (el) |
| PL (1) | PL1870409T3 (el) |
| PT (1) | PT1870409E (el) |
| RS (1) | RS51389B (el) |
| RU (1) | RU2409573C2 (el) |
| SI (1) | SI1870409T1 (el) |
| WO (1) | WO2006112442A1 (el) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070015782A1 (en) * | 2005-04-15 | 2007-01-18 | Eisai Co., Ltd. | Benzimidazole compound |
| WO2007122686A1 (ja) * | 2006-04-14 | 2007-11-01 | Eisai R & D Management Co., Ltd. | ベンズイミダゾール化合物 |
| JP2009196894A (ja) * | 2006-10-13 | 2009-09-03 | Eisai R & D Management Co Ltd | スルフィニルベンズイミダゾール化合物またはその塩の製造方法 |
| WO2008047681A1 (fr) * | 2006-10-13 | 2008-04-24 | Eisai R & D Management Co., Ltd. | Benzimidazole présentant une activité inhibitrice de la sécrétion d'acide gastrique |
| TWI546306B (zh) * | 2007-04-11 | 2016-08-21 | 第一三共股份有限公司 | 神經胺酸衍生物之製造方法 |
| PL2071986T3 (pl) * | 2007-12-18 | 2012-07-31 | Nestec Sa | System do wytwarzania napoju ze składników podtrzymywanych przez zakodowaną wkładkę |
| WO2012003274A1 (en) | 2010-07-01 | 2012-01-05 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of pi3k activity |
| US9586947B2 (en) | 2012-09-04 | 2017-03-07 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Imidazoline derivatives, preparation methods thereof, and their applications in medicine |
| EP2803666B1 (de) | 2013-05-17 | 2016-04-27 | Symrise AG | Cyclische Acetale und Ketale sowie deren Verwendung als Riechstoff |
| JP6377334B2 (ja) * | 2013-10-25 | 2018-08-22 | 東洋鋼鈑株式会社 | 非線形光学色素、フォトリフラクティブ材料組成物、フォトリフラクティブ基材およびホログラム記録媒体 |
| CN107428726B (zh) * | 2014-12-26 | 2021-03-16 | 国立大学法人东京大学 | 光学活性的质子泵抑制剂化合物的制备方法 |
| US10544113B2 (en) | 2016-03-07 | 2020-01-28 | National Health Research Institute | Thiazolidinone compounds and use thereof |
| CN112457175B (zh) * | 2020-11-03 | 2022-09-02 | 山东师范大学 | 一种制备1,3-二苄氧基-2-丙酮的方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8300736D0 (sv) | 1983-02-11 | 1983-02-11 | Haessle Ab | Novel pharmacologically active compounds |
| DE3579436D1 (de) | 1984-12-18 | 1990-10-04 | Otsuka Pharma Co Ltd | Tetrahydrochinolin- derivate, verfahren zu deren herstellung und diese enthaltende antimagengeschwuerzusammensetzungen. |
| JPS62277322A (ja) | 1986-02-13 | 1987-12-02 | Takeda Chem Ind Ltd | 安定化された腸溶性抗潰瘍固形組成物 |
| JPS62207271A (ja) | 1986-03-06 | 1987-09-11 | Yamanouchi Pharmaceut Co Ltd | ２−ピリジルメチルチオ基または２−ピリジルメチルスルフイニル基で置換された縮合環化合物 |
| GB2189699A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| JPH0643426B2 (ja) | 1986-07-25 | 1994-06-08 | 東京田辺製薬株式会社 | イミダゾ〔４，５−ｂ〕ピリジン誘導体、その製造法及びそれを含有する抗潰瘍剤 |
| US5026560A (en) | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
| JPH0222273A (ja) * | 1987-07-21 | 1990-01-25 | Yoshitomi Pharmaceut Ind Ltd | ピリジン化合物およびその医薬用途 |
| JPH0633261B2 (ja) | 1988-01-22 | 1994-05-02 | 東京田辺製薬株式会社 | 新規なイミダゾ［４，５−ｂピリジン誘導体、その製造法及びそれを含有する抗潰瘍剤 |
| SE9002206D0 (sv) * | 1990-06-20 | 1990-06-20 | Haessle Ab | New compounds |
| ATE184602T1 (de) | 1990-06-20 | 1999-10-15 | Astra Ab | Dialkoxypyridinylbenzimidazolderivate, verfahren zur herstellung und ihre pharmazeutische verwendung |
| JP2820829B2 (ja) | 1991-03-07 | 1998-11-05 | 武田薬品工業株式会社 | 有核散剤およびその製造方法 |
| JPH05117268A (ja) * | 1991-10-22 | 1993-05-14 | Yoshitomi Pharmaceut Ind Ltd | ピリジン化合物 |
| JPH05177268A (ja) | 1992-01-09 | 1993-07-20 | Amada Co Ltd | 縦型パンチプレス |
| EP1072257A1 (en) | 1998-04-17 | 2001-01-31 | Taisho Pharmaceutical Co., Ltd | Multiple-unit sustained release tablets |
| KR100472126B1 (ko) | 1998-08-10 | 2005-03-08 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 양성자 펌프 억제제의 프로드러그 |
| TW404832B (en) | 1999-01-27 | 2000-09-11 | Nang Kuang Pharmaceutical Co L | The oral medicine with good stability cotaining the omeprazole or the analogues |
| CA2362930C (en) | 1999-02-26 | 2010-10-05 | Nitromed, Inc. | Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use |
| US6852739B1 (en) | 1999-02-26 | 2005-02-08 | Nitromed Inc. | Methods using proton pump inhibitors and nitric oxide donors |
| ES2168043B1 (es) | 1999-09-13 | 2003-04-01 | Esteve Labor Dr | Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido. |
| AU2001296908A1 (en) | 2000-09-29 | 2002-04-08 | Geneva Pharmaceuticals, Inc. | Proton pump inhibitor formulation |
| JP4331930B2 (ja) | 2001-10-17 | 2009-09-16 | 武田薬品工業株式会社 | 酸に不安定な薬物の高含量顆粒 |
| ES2392960T3 (es) | 2001-10-17 | 2012-12-17 | Takeda Pharmaceutical Company Limited | Gránulos que contienen gran cantidad de compuesto químico inestable en medio ácido |
| JP2003137771A (ja) | 2001-10-30 | 2003-05-14 | Nichiko Pharmaceutical Co Ltd | 難溶性薬物用医薬製剤 |
| MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| SE0203065D0 (sv) | 2002-10-16 | 2002-10-16 | Diabact Ab | Gastric acid secretion inhibiting composition |
| US20040166162A1 (en) | 2003-01-24 | 2004-08-26 | Robert Niecestro | Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid |
| WO2004080439A1 (ja) | 2003-03-12 | 2004-09-23 | Takeda Pharmaceutical Company Limited | 高濃度に活性成分を球形核に付着させた医薬組成物 |
| JPWO2005011637A1 (ja) | 2003-08-04 | 2006-09-14 | エーザイ株式会社 | 用時分散型製剤 |
| US20070015782A1 (en) * | 2005-04-15 | 2007-01-18 | Eisai Co., Ltd. | Benzimidazole compound |
-
2006
- 2006-04-14 US US11/403,815 patent/US20070015782A1/en not_active Abandoned
- 2006-04-17 DK DK06731998.8T patent/DK1870409T3/da active
- 2006-04-17 PL PL06731998T patent/PL1870409T3/pl unknown
- 2006-04-17 WO PCT/JP2006/308069 patent/WO2006112442A1/ja active Application Filing
- 2006-04-17 NZ NZ561920A patent/NZ561920A/en not_active IP Right Cessation
- 2006-04-17 ME MEP-2010-346A patent/ME01855B/me unknown
- 2006-04-17 EP EP06731998A patent/EP1870409B1/en active Active
- 2006-04-17 DE DE602006014261T patent/DE602006014261D1/de active Active
- 2006-04-17 KR KR1020077023561A patent/KR101285696B1/ko active IP Right Grant
- 2006-04-17 PT PT06731998T patent/PT1870409E/pt unknown
- 2006-04-17 CA CA2602610A patent/CA2602610C/en active Active
- 2006-04-17 AU AU2006237974A patent/AU2006237974B2/en active Active
- 2006-04-17 RS RSP-2010/0346A patent/RS51389B/en unknown
- 2006-04-17 JP JP2007528143A patent/JP4949246B2/ja active Active
- 2006-04-17 SI SI200630712T patent/SI1870409T1/sl unknown
- 2006-04-17 RU RU2007138053/04A patent/RU2409573C2/ru active
- 2006-04-17 BR BRPI0608400A patent/BRPI0608400B8/pt active IP Right Grant
- 2006-04-17 ES ES06731998T patent/ES2344467T3/es active Active
- 2006-09-14 US US11/520,838 patent/US7425634B2/en active Active
-
2007
- 2007-09-25 IL IL186282A patent/IL186282A/en active IP Right Grant
- 2007-11-15 NO NO20075904A patent/NO339502B1/no not_active IP Right Cessation
-
2008
- 2008-07-17 HK HK08107942.6A patent/HK1117826A1/xx not_active IP Right Cessation
- 2008-08-11 US US12/189,590 patent/US8124780B2/en not_active Expired - Fee Related
-
2010
- 2010-06-11 CY CY20101100543T patent/CY1110074T1/el unknown
- 2010-07-15 HR HR20100389T patent/HRP20100389T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100389T1 (hr) | Spojevi benzimidazola | |
| JP4432051B2 (ja) | Ｎ−フェニル−アリールスルフォンアミド化合物、その化合物を有効成分として含有する薬剤、その化合物の合成中間体およびその製造方法 | |
| JP2008535774A5 (el) | ||
| RU2006101890A (ru) | Производные тиазолилпиперидина в качестве ингибиторов мпб | |
| RU2007141655A (ru) | Комбинированное применение производного простагландина и ингибитора протонового насоса для лечения желудочно-кишечных заболеваний | |
| EA003697B1 (ru) | Дизамещенные бициклические гетероциклы, их получение и применение в качестве лекарственных средств | |
| AR076908A1 (es) | Aril-piridinas como inhibidoras de sintasa de aldosterona | |
| AU2003259154C1 (en) | Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor | |
| JP2008508352A5 (el) | ||
| RU2062778C1 (ru) | Производные бензимидазола и способ их получения | |
| AR110149A2 (es) | Composición catártica | |
| AR074819A1 (es) | Compuestos heterociclicos antivirales | |
| JP2008524249A5 (el) | ||
| MX2009000080A (es) | Derivados de bencimidazol como inhibidores selectivos de la bomba de acido. | |
| PE20081475A1 (es) | Arilamidas sustituidas por tiazol u oxazol | |
| TW200732326A (en) | Chromane substituted benzimidazole derivatives | |
| JP2007500703A5 (el) | ||
| ATE442140T1 (de) | Chroman-substituierte benzimidazolderivate als säurepumpenantagonisten | |
| JP2012501296A5 (el) | ||
| KR101777971B1 (ko) | 이미다조[1,2-a]피리딘 유도체, 이의 제조방법 및 이의 용도 | |
| KR20180041747A (ko) | 카르복시 치환된 (헤테로) 방향족 고리 유도체 및 이의 제조 방법과 용도 | |
| AU604771B2 (en) | Pyridinylphenylthio and pyridinylphenylsulphinyl benzimidazone derivatives | |
| PE20231652A1 (es) | Nuevo inhibidor de la secrecion de acido y uso del mismo | |
| NO20072764L (no) | Kromanderivater som er nyttige syrepumpeantagonister | |
| TWI297008B (en) | Novel tetrahydroisoquinoline derivates and pharmaceutical use thereof |